Novocure Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novocure Ltd (NVCR)
Assess today's live Novocure Ltd (NVCR) share price, performance and insights using our live NASDAQ: NVCR stock exchange data.
Analyse the historical data and Novocure Ltd share price performance charts on this page. Our technical summary section provides analysis on Novocure Ltd share price buy/sell indicators using real-time data (or discuss the Novocure Ltd (NVCR) stock price today with other investors in the Novocure Ltd NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NVCR share price (ISIN: JE00BYSS4X48) to enhance your trading decisions with our free investment tools and resources.
What Is the Novocure Ltd Share Price Today?
The Novocure Ltd share price today is 13.27.
What Is the Stock Symbol for Novocure Ltd
The stock symbol (or 'ticker') for Novocure Ltd is "NVCR."
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Novocure Ltd share price performance charts on this page. Our technical summary section provides analysis on Novocure Ltd share price buy/sell indicators using real-time data (or discuss the Novocure Ltd (NVCR) stock price today with other investors in the Novocure Ltd NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NVCR share price (ISIN: JE00BYSS4X48) to enhance your trading decisions with our free investment tools and resources.
What Is the Novocure Ltd Share Price Today?
The Novocure Ltd share price today is 13.27.
What Is the Stock Symbol for Novocure Ltd
The stock symbol (or 'ticker') for Novocure Ltd is "NVCR."
What Stock Exchange Does Novocure Ltd Trade On?
Novocure Ltd is listed and trades on the NASDAQ stock exchange.
Is Novocure Ltd a Good Stock to Buy?
Determining whether Novocure Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.98
13.39
52 wk Range
10.70
32.06
NVCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.9813.39
52 wk Range
10.7032.06
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVCR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
24.79
Upside
+86.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form 13G NovoCure Ltd. For: 13 November
- Investing.com
- Novocure Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Novocure Ltd Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Novocure Ltd SWOT Analysis
Innovative Cancer Tech | Novocure's Tumor Treating Fields therapy revolutionizes oncology, with promising applications beyond glioblastoma multiforme treatment |
Market Expansion | Explore Novocure's strategic growth in Europe, particularly France, and potential opportunities in Italy and Spain's healthcare markets |
Financial Performance | Analysts project 16.7% revenue growth for 2024, with price targets ranging from $24 to $40, despite current operational losses |
Future Prospects | Delve into Novocure's product pipeline, including new arrays for lung cancer and anticipated FDA approvals, shaping its competitive edge |
Novocure Ltd Earnings Call Summary for Q4/2024
- Q4 revenue of $161M exceeded forecasts, up 21% YoY, despite EPS miss of -$0.61 vs -$0.36 expected
- Full year 2024 revenue reached $605M, a 19% increase, with strong international growth and $960M cash on hand
- Company expects low to mid-single digit growth in GBM business for 2025, with significant revenue ramp from lung cancer in 2026
- Novocure aims for positive adjusted EBITDA as new indication revenues materialize, expanding beyond single GBM focus
- Stock showed resilience with minor premarket decline; analysts maintain positive outlook despite ongoing profitability challenges
Last Updated: 27/02/2025, 14:14
Read Full TranscriptCompare NVCR to Peers and Sector
Metrics to compare | NVCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.4x | −3.0x | −0.6x | |
PEG Ratio | 0.54 | −0.16 | 0.00 | |
Price/Book | 4.4x | 4.2x | 2.6x | |
Price / LTM Sales | 2.3x | 3.6x | 3.2x | |
Upside (Analyst Target) | 80.9% | 51.1% | 41.8% | |
Fair Value Upside | Unlock | 11.8% | 5.1% | Unlock |
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 24.79
(+86.78% Upside)
Earnings
Latest Release
Oct 30, 2025
EPS / Forecast
-0.33 / -0.42
Revenue / Forecast
167.00M / 158.54M
People Also Watch
FAQ
What Is the Novocure Ltd (NVCR) Share Price Today?
The live Novocure Ltd share price today is 13.27
What Stock Exchange Does Novocure Ltd (NVCR) Trade On?
Novocure Ltd is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Novocure Ltd?
The stock symbol (also called a 'ticker') for Novocure Ltd is "NVCR."
What Is the Current Novocure Ltd Market Cap?
As of today, Novocure Ltd market capitalisation is 1.49B.
What Is Novocure Ltd's (NVCR) Earnings Per Share (TTM)?
The Novocure Ltd EPS is currently -1.61 (Trailing Twelve Months).
When Is the Next Novocure Ltd Earnings Date?
Novocure Ltd's next earnings report will be released on 19 Feb 2026.
Is NVCR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Novocure Ltd moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Novocure Ltd Stock Split?
Novocure Ltd has split 0 times. (See the NVCR stock split history page for full effective split date and price information.)
How Many Employees Does Novocure Ltd Have?
Novocure Ltd has 1488 employees.
What is the current trading status of Novocure Ltd (NVCR)?
As of 24 Dec 2025, Novocure Ltd (NVCR) is trading at a price of 13.27, with a previous close of 13.44. The stock has fluctuated within a day range of 12.98 to 13.39, while its 52-week range spans from 10.70 to 32.06.
What Is Novocure Ltd (NVCR) Price Target According to Analysts?
The average 12-month price target for Novocure Ltd is USD24.78571, with a high estimate of USD42 and a low estimate of USD13.5. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +86.78% Upside potential.
What Is the NVCR After Hours Price?
NVCR's last after hours stock price is 12.90, the stock has decreased by -0.37, or -2.77%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.